Introduction: Analytical Strategies for Sameness Study are fundamental in demonstrating that a generic drug is equivalent to its Reference Listed […]
Analytical Strategies to Prove Sameness Between Generic and RLD Read More »
Introduction Choosing a CDMO for Long Acting Injectable Formulation Development is an important strategic decision in modern drug delivery. These
How to Choose a CDMO for Long Acting Injectable Formulation Development Read More »
Introduction: Long Acting Injectable Formulation Development is becoming a preferred strategy for pharmaceutical companies aiming to improve patient adherence and
Long Acting Injectable Formulation Development: Complete Guide for Pharma Companies Read More »
Introduction: Active Ingredient Sameness in ANDA is demonstrated by proving that the generic drug’s API is identical to the Reference
How to Demonstrate Active Ingredient Sameness in an ANDA Submission Read More »
Introduction: Why Long Acting Injectables Market Trends Are Shifting the Generic Pharma Calculus The Long Acting Injectables Market Trends observed
Future of Long-Acting Injectables & Generic Opportunities Read More »
Choosing the right Contract Research Organization (CRO) for complex injectables is a strategic decision that goes far beyond basic outsourcing.
Selecting the Right CRO for Complex Generic Injectables Read More »
Introduction: Why Lupron Depot Development Failures Persist Lupron Depot Development Failures continue to shape the reality of long-acting injectable (LAI)
Common Failures in Leuprolide Depot Generic Development Read More »
Introduction: Sameness Evaluation in ANDA is the scientific and regulatory process of proving that a generic drug’s active ingredient is
Sameness Evaluation in ANDA: Complete Guide for Active Ingredient Assessment Read More »
Introduction Long Acting Injectables Characterization focuses on understanding microstructure, release mechanisms, and polymer-drug interactions using advanced analytical techniques. This approach
Advanced Characterization Techniques for Long Acting Injectables Products Read More »
Introduction: Why Risk Allocation Matters More Than Risk Avoidance in Generic Development In complex generic pharmaceutical development, risk cannot be
Risk-Sharing Collaboration Models in Complex Generic Development Read More »
